Not a good buy right now: the stock is technically extended (short-term overbought), sitting near/just below key resistance after an after-hours drop, while probabilistic near-term trend data points to further downside.
If you’re impatient and want exposure immediately, this is a poor entry location; risk/reward is skewed against chasing here ahead of earnings (2026-02-23 after hours).
Best read from the full dataset: strong business momentum and upbeat guidance, but near-term trading setup and positioning (hedge fund selling) argue against buying today.
Technical Analysis
Trend: Bullish structure (SMA_5 > SMA_20 > SMA_200) and MACD histogram positive and expanding (0.503) → underlying uptrend remains intact.
Momentum/extension: RSI_6 at 78.377 signals a stretched/overbought condition (despite the label in the feed), which often precedes pullbacks or consolidation.
Key levels: Pivot 73.285 (near-term “line in the sand” support). Resistance: R1 ~76.883 and R2 ~79.106. Post-market price (75.38) is back below R1, suggesting a failed push that can invite mean reversion.
Pattern-based forward bias (provided): 70% chance of -0.72% next day, -4.59% next week, -6.41% next month → near-term odds favor downside rather than a clean continuation higher.
Positioning/sentiment: Put/Call ratios are very low (OI PCR 0.44; Volume PCR 0.09) → options market is positioned bullish (more call interest/flow than puts).
Volatility: 30D IV ~41.14 vs historical vol ~32.61 and IV percentile ~66.53 → options are pricing elevated volatility; market expects bigger-than-usual moves (notably with earnings approaching).
Activity: Today’s options volume (296) is ~68.5% of 30D average → not a “panic” tape today; sentiment is bullish but not showing unusually heavy participation.
Morgan Stanley (2026-01-08): Overweight, price target cut to $75 from $79 (still constructive but trimming).
TD Cowen (2026-01-08): Buy, price target raised to $90 from $79 (bullish on multi-year upside framework).
Goldman Sachs (2025-12-04): Downgraded to Sell with $56 target (bear case centered on post-2030 Enhanze royalty cliff and demanding terminal value assumptions).
Wall Street pros: Strong guidance upgrades, high-margin royalty-like model, consistent growth and profitability.
Wall Street cons: Concentration/contract roll-off risk post-2030 and valuation sensitivity to long-dated partner-product success; mixed near-term conviction shown by diverging targets.
Influential/political trading check: No recent congress trading data available; insiders reported as neutral (no significant trend).
Wall Street analysts forecast HALO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78 USD with a low forecast of 56 USD and a high forecast of 92 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast HALO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78 USD with a low forecast of 56 USD and a high forecast of 92 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 78.420
Low
56
Averages
78
High
92
Current: 78.420
Low
56
Averages
78
High
92
Morgan Stanley
Overweight
downgrade
$79 -> $75
AI Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$79 -> $75
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Halozyme to $75 from $79 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
TD Cowen
Buy
upgrade
$79 -> $90
2026-01-08
Reason
TD Cowen
Price Target
$79 -> $90
2026-01-08
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Halozyme to $90 from $79 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HALO
